Non-specificity of drug-Target interactions - Consequences for drug discovery

Gerald Maggiora, Vijay Gokhale

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Dealing with the complexity of the human biosystem in drug discovery is a daunting task. At best we have an imperfect picture of its underlying physiology and pharmacology, which raises the question of how to identify potential drug compounds from the vast sea of xenobiotics that populate chemical space. The dominant approach is still based on the single-Target paradigm, which has a number of inherent problems not the least of which is the difficulty of altering disease phenotypes by intervening at single targets embedded within complex, interconnected biological pathways. While newer multi-Target approaches address some of the problems, they are not entirely without problems of their own. Superimposed on all of these difficulties is a surprising lack of compound and target specificity that the growing amount of data clearly shows is a more pervasive problem than has generally been assumed. And although sophisticated phenotypic screening methods are being developed in an effort to deal with some of these issues, many remain refractory.

Original languageEnglish (US)
Title of host publicationFrontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath
PublisherAmerican Chemical Society
Pages91-142
Number of pages52
Volume1222
ISBN (Electronic)9780841231412
StatePublished - 2016

Publication series

NameACS Symposium Series
Volume1222
ISSN (Print)00976156
ISSN (Electronic)19475918

Fingerprint

Physiology
Xenobiotics
Refractory materials
Screening
Pharmaceutical Preparations
Drug Discovery

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Maggiora, G., & Gokhale, V. (2016). Non-specificity of drug-Target interactions - Consequences for drug discovery. In Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath (Vol. 1222, pp. 91-142). (ACS Symposium Series; Vol. 1222). American Chemical Society.

Non-specificity of drug-Target interactions - Consequences for drug discovery. / Maggiora, Gerald; Gokhale, Vijay.

Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath. Vol. 1222 American Chemical Society, 2016. p. 91-142 (ACS Symposium Series; Vol. 1222).

Research output: Chapter in Book/Report/Conference proceedingChapter

Maggiora, G & Gokhale, V 2016, Non-specificity of drug-Target interactions - Consequences for drug discovery. in Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath. vol. 1222, ACS Symposium Series, vol. 1222, American Chemical Society, pp. 91-142.
Maggiora G, Gokhale V. Non-specificity of drug-Target interactions - Consequences for drug discovery. In Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath. Vol. 1222. American Chemical Society. 2016. p. 91-142. (ACS Symposium Series).
Maggiora, Gerald ; Gokhale, Vijay. / Non-specificity of drug-Target interactions - Consequences for drug discovery. Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath. Vol. 1222 American Chemical Society, 2016. pp. 91-142 (ACS Symposium Series).
@inbook{baa54edc50414a858867e0252c84f5ef,
title = "Non-specificity of drug-Target interactions - Consequences for drug discovery",
abstract = "Dealing with the complexity of the human biosystem in drug discovery is a daunting task. At best we have an imperfect picture of its underlying physiology and pharmacology, which raises the question of how to identify potential drug compounds from the vast sea of xenobiotics that populate chemical space. The dominant approach is still based on the single-Target paradigm, which has a number of inherent problems not the least of which is the difficulty of altering disease phenotypes by intervening at single targets embedded within complex, interconnected biological pathways. While newer multi-Target approaches address some of the problems, they are not entirely without problems of their own. Superimposed on all of these difficulties is a surprising lack of compound and target specificity that the growing amount of data clearly shows is a more pervasive problem than has generally been assumed. And although sophisticated phenotypic screening methods are being developed in an effort to deal with some of these issues, many remain refractory.",
author = "Gerald Maggiora and Vijay Gokhale",
year = "2016",
language = "English (US)",
volume = "1222",
series = "ACS Symposium Series",
publisher = "American Chemical Society",
pages = "91--142",
booktitle = "Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath",

}

TY - CHAP

T1 - Non-specificity of drug-Target interactions - Consequences for drug discovery

AU - Maggiora, Gerald

AU - Gokhale, Vijay

PY - 2016

Y1 - 2016

N2 - Dealing with the complexity of the human biosystem in drug discovery is a daunting task. At best we have an imperfect picture of its underlying physiology and pharmacology, which raises the question of how to identify potential drug compounds from the vast sea of xenobiotics that populate chemical space. The dominant approach is still based on the single-Target paradigm, which has a number of inherent problems not the least of which is the difficulty of altering disease phenotypes by intervening at single targets embedded within complex, interconnected biological pathways. While newer multi-Target approaches address some of the problems, they are not entirely without problems of their own. Superimposed on all of these difficulties is a surprising lack of compound and target specificity that the growing amount of data clearly shows is a more pervasive problem than has generally been assumed. And although sophisticated phenotypic screening methods are being developed in an effort to deal with some of these issues, many remain refractory.

AB - Dealing with the complexity of the human biosystem in drug discovery is a daunting task. At best we have an imperfect picture of its underlying physiology and pharmacology, which raises the question of how to identify potential drug compounds from the vast sea of xenobiotics that populate chemical space. The dominant approach is still based on the single-Target paradigm, which has a number of inherent problems not the least of which is the difficulty of altering disease phenotypes by intervening at single targets embedded within complex, interconnected biological pathways. While newer multi-Target approaches address some of the problems, they are not entirely without problems of their own. Superimposed on all of these difficulties is a surprising lack of compound and target specificity that the growing amount of data clearly shows is a more pervasive problem than has generally been assumed. And although sophisticated phenotypic screening methods are being developed in an effort to deal with some of these issues, many remain refractory.

UR - http://www.scopus.com/inward/record.url?scp=84990834222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990834222&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84990834222

VL - 1222

T3 - ACS Symposium Series

SP - 91

EP - 142

BT - Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jurgen Bajorath

PB - American Chemical Society

ER -